ANAPTYSBIO, INC. DelveInsight's, "Acne Vulgaris - Pipeline Insight, 2023," report provides comprehensive insights about 22+ companies and 22+ pipeline drugs in Acne Vulgaris pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
DelveInsight's, "Acne Vulgaris - Pipeline Insight, 2023," report provides comprehensive insights about 22+ companies and 22+ pipeline drugs in Acne Vulgaris pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Some of the Key Highlights*The Key Companies working in the Acne Vulgaris Pipeline include Novan, Bausch Health AOBiome,
Acne Vulgaris Overview
Acne vulgaris is an inflammatory disorder of the pilosebaceous unit, which runs a chronic course and it is self-limiting. Acne vulgaris is triggered by Cutibacterium acnes in adolescence, under the influence of normal circulating dehydroepiandrosterone (DHEA). It is a very common skin disorder which can present with inflammatory and non-inflammatory lesions chiefly on the face but can also occur on the upper arms, trunk, and back. Acne may appear in adolescence, and it persists through the early thirties. Acne is more common in males than in females. Urban populations are more affected than rural populations. About 20% of the affected individuals develop severe acne, which results in scarring. Some races appear to be more affected than others. Acne occurs by hypersensitivity of the sebaceous glands to a normal circulating level of androgens, which are aggravated by P. acnes and inflammation. Acne vulgaris is diagnosed clinically. However, in women of childbearing age, one should ask for a history of hirsutism or dysmenorrhea. If positive, then levels of testosterone, LH, FSH, and DHEA should be ordered. Topical retinoids like retinoic acid, adapalene, and tretinoin are used alone or with other topical antibiotics or benzoyl peroxide. Retinoic acid is the best comedolytic agent, available as 0.025%, 0.05%, 0.1% cream, and gel. Azelaic acid is antimicrobial and comedolytic available in 15% or 20% gel. It can also be used in postinflammatory pigmentation of acne. An oral contraceptive containing low-dose estrogen 20 mcg along with cyproterone acetate as anti-androgens are used for severe recurrent acne. There are approx. 22+ key companies that are developing therapies for Acne Vulgaris. The companies which have their Acne vulgaris drug candidates in the most advanced stage, i.e. Phase III include,
Phases
DelveInsight's report covers around 22+ products under different phases of clinical development like*Late stage products (Phase III) *Mid-stage products (Phase II) *Early-stage product (Phase I) along with the details of *Pre-clinical and Discovery stage candidates *Discontinued & Inactive candidates *Route of Administration
Acne Vulgaris pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as*Oral *Parenteral *Intravitreal *Subretinal *Topical *Molecule Type
Products have been categorized under various Molecule types such as*Monoclonal Antibody *Peptides *Polymer *Small molecule *Gene therapy *Product Type
Drugs have been categorized under various product types like Mono, Combination, and Mono/Combination.
Acne Vulgaris Key Companies*Novan *
Acne Vulgaris Therapies*IDP126 *DMT310
And many others
Table of Contents*Key Insights *Report Introduction *Executive Summary of Acne Vulgaris *Disease Background and Overview *Epidemiology and patient population *Acne Vulgaris Emerging Therapies *Acne Vulgaris Market Outlook *Market Access and Reimbursement of Therapies *Appendix *Acne Vulgaris Report Methodology *DelveInsight Capabilities *Disclaimer
Click here to read more about Acne Vulgaris Market
Media Contact
Company
Contact Person:
Email: info@delveinsight.com
Phone: 919650213330
Address:
City:
State:
Country:
Website: https://www.delveinsight.com/consulting/due-diligence-services
Source: www.abnewswire.com
.
(C) 2023 M2 COMMUNICATIONS, source
